Adaptive Biotechnologies Corporation Insider Trading

ADPT

Last 12 months

Insiders sold $130M and bought nothing on the open market.

74% of the selling was scheduled in advance under 10b5-1 plans. CEO and Chairman Chad M Robins sold $14.9M on Aug 18, 22% of their stake, outside a plan. The last open-market buy by an executive or director was in Jul 2019.

Net open-market

−$130M

0 buys · 79 sales

Under a 10b5-1 plan

74%

of the value sold

Insiders who bought / sold

0 / 11

executives and directors

Last open-market buy

Jul 2019

Jul 1, 2019

Get an email when ADPT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 30 – Nov 3	Julie Rubinstein President and COO	Sold10b5-1 plan 5 parts	35,643	$26.06 average	929K	8.6%	Form 4
Oct 27 – 29	Julie Rubinstein President and COO	Sold10b5-1 plan 5 parts	35,643	$28.00 average	998K	8.6%	Form 4
Oct 22 – 26	Julie Rubinstein President and COO	Sold10b5-1 plan 6 parts	35,643	$25.18 average	897K	8.6%	Form 4
Oct 19 – 21	Julie Rubinstein President and COO	Sold10b5-1 plan 5 parts	35,643	$24.66 average	879K	8.6%	Form 4
Oct 14 – 16	Julie Rubinstein President and COO	Sold10b5-1 plan 5 parts	35,643	$25.18 average	897K	8.6%	Form 4
Oct 9 – 13	Julie Rubinstein President and COO	Sold10b5-1 plan 4 parts	35,643	$25.81 average	920K	8.6%	Form 4
Oct 6 – 8	Julie Rubinstein President and COO	Sold10b5-1 plan 6 parts	35,643	$26.60 average	948K	8.6%	Form 4
Oct 6	Susan Bobulsky Chief Commercial Officer, MRD	Sold10b5-1 plan	6,444	$30.00	193K	1.6%	Form 4
Oct 1 – 5	Julie Rubinstein President and COO	Sold10b5-1 plan 5 parts	35,643	$28.46 average	$1.01M	8.6%	Form 4
Oct 1	Francis Lo Chief People Officer	Sold10b5-1 plan 2 parts	26,792	$28.28 average	758K	11%	Form 4
Sep 16	Francis Lo Chief People Officer	Sold10b5-1 plan 2 parts	115,406	$28.06 average	$3.24M	34%	Form 4
Sep 15	Susan Bobulsky Chief Commercial Officer, MRD	Sold10b5-1 plan	1,195	$27.00	32K	0.3%	Form 4
Aug 26	Katey Einterz Owen Director	SoldNo plan	9,615	$26.00	250K	11%	Form 4
Aug 18	Robert Hershberg Director	SoldNo plan 2 parts	30,664	$24.40 average	748K	40%	Form 4
Aug 17 – 18	Chad M Robins CEO and Chairman	SoldNo plan 4 parts	600,000	$24.80 average	$14.9M	22%	Form 4
Aug 17	Peter M Neupert Director	SoldNo plan 3 parts	124,690	$25.15 average	$3.14M	49%	Form 4
Aug 10	Susan Bobulsky Chief Commercial Officer, MRD	Sold10b5-1 plan	3,000	$25.00	75K	0.8%	Form 4
Jul 30	Susan Bobulsky Chief Commercial Officer, MRD	Sold10b5-1 plan	1,299	$24.00	31K	0.3%	Form 4
Jul 21	Harlan S Robins Chief Scientific Officer	Sold10b5-1 plan 2 parts	492,400	$21.89 average	$10.8M	38%	Form 4
Jul 16	Susan Bobulsky Chief Commercial Officer, MRD	Sold10b5-1 plan	5,000	$23.00	115K	1.2%	Form 4
Jul 15	Francis Lo Chief People Officer	Sold10b5-1 plan	105,762	$22.59	$2.39M	31%	Form 4
Jul 2	Harlan S Robins Chief Scientific Officer	Sold10b5-1 plan 2 parts	386,240	$22.01 average	$8.5M	27%	Form 4
Jul 1 – 2	Francis Lo Chief People Officer	Sold10b5-1 plan 3 parts	95,842	$22.51 average	$2.16M	29%	Form 4
Jul 1	Susan Bobulsky Chief Commercial Officer, MRD	Sold10b5-1 plan	487	$22.00	11K	0.1%	Form 4
Jun 26 – 29	Sharon Benzeno Chief Commercial Ofc Imm Med	Sold10b5-1 plan 2 parts	165,802	$21.13 average	$3.5M	43%	Form 4
Jun 25	Susan Bobulsky Chief Commercial Officer, MRD	Sold10b5-1 plan	5,000	$20.50	103K	1.2%	Form 4
Jun 25	Michelle Renee Griffin Director	Sold10b5-1 plan	52,084	$20.18	$1.05M	77%	Form 4
Jun 15 – 16	Harlan S Robins Chief Scientific Officer	Sold10b5-1 plan 2 parts	106,160	$17.41 average	$1.85M	7.0%	Form 4
Jun 11	Susan Bobulsky Chief Commercial Officer, MRD	Sold10b5-1 plan	5,000	$19.00	95K	1.2%	Form 4
Jun 4	Susan Bobulsky Chief Commercial Officer, MRD	Sold10b5-1 plan	11,000	$18.00	198K	2.6%	Form 4
Jun 4	Francis Lo Chief People Officer	Sold10b5-1 plan	39,741	$17.49	695K	14%	Form 4
May 18	Kyle Piskel Chief Financial Officer	SoldNo plan	3,115	$13.04	41K	1.2%	Form 4
Apr 27	Julie Rubinstein President and COO	Sold10b5-1 plan	19,037	$14.23	271K	4.8%	Form 4
Apr 22 – 24	Julie Rubinstein President and COO	Sold10b5-1 plan 3 parts	57,180	$13.96 average	798K	13%	Form 4
Apr 17 – 21	Julie Rubinstein President and COO	Sold10b5-1 plan 3 parts	69,061	$14.60 average	$1.01M	15%	Form 4
Apr 14 – 16	Julie Rubinstein President and COO	Sold10b5-1 plan 3 parts	57,180	$14.45 average	826K	12%	Form 4
Apr 9 – 13	Julie Rubinstein President and COO	Sold10b5-1 plan 6 parts	57,180	$13.26 average	758K	12%	Form 4
Apr 8	Harlan S Robins Chief Scientific Officer	Sold10b5-1 plan	10,000	$14.85	149K	0.7%	Form 4
Apr 8	Francis Lo Chief People Officer	Sold10b5-1 plan	22,564	$15.07	340K	7.6%	Form 4
Apr 6 – 8	Julie Rubinstein President and COO	Sold10b5-1 plan 4 parts	69,061	$14.34 average	991K	14%	Form 4

Oct 30 – Nov 310b5-1 plan
Julie Rubinstein
President and COO · sold 35,643 at avg $26.06
929K
8.6% of stake
Oct 27 – 2910b5-1 plan
Julie Rubinstein
President and COO · sold 35,643 at avg $28.00
998K
8.6% of stake
Oct 22 – 2610b5-1 plan
Julie Rubinstein
President and COO · sold 35,643 at avg $25.18
897K
8.6% of stake
Oct 19 – 2110b5-1 plan
Julie Rubinstein
President and COO · sold 35,643 at avg $24.66
879K
8.6% of stake
Oct 14 – 1610b5-1 plan
Julie Rubinstein
President and COO · sold 35,643 at avg $25.18
897K
8.6% of stake
Oct 9 – 1310b5-1 plan
Julie Rubinstein
President and COO · sold 35,643 at avg $25.81
920K
8.6% of stake
Oct 6 – 810b5-1 plan
Julie Rubinstein
President and COO · sold 35,643 at avg $26.60
948K
8.6% of stake
Oct 610b5-1 plan
Susan Bobulsky
Chief Commercial Officer, MRD · sold 6,444 at $30.00
193K
1.6% of stake
Oct 1 – 510b5-1 plan
Julie Rubinstein
President and COO · sold 35,643 at avg $28.46
$1.01M
8.6% of stake
Oct 110b5-1 plan
Francis Lo
Chief People Officer · sold 26,792 at avg $28.28
758K
11% of stake
Sep 1610b5-1 plan
Francis Lo
Chief People Officer · sold 115,406 at avg $28.06
$3.24M
34% of stake
Sep 1510b5-1 plan
Susan Bobulsky
Chief Commercial Officer, MRD · sold 1,195 at $27.00
32K
0.3% of stake
Aug 26No plan
Katey Einterz Owen
Director · sold 9,615 at $26.00
250K
11% of stake
Aug 18No plan
Robert Hershberg
Director · sold 30,664 at avg $24.40
748K
40% of stake
Aug 17 – 18No plan
Chad M Robins
CEO and Chairman · sold 600,000 at avg $24.80
$14.9M
22% of stake
Aug 17No plan
Peter M Neupert
Director · sold 124,690 at avg $25.15
$3.14M
49% of stake
Aug 1010b5-1 plan
Susan Bobulsky
Chief Commercial Officer, MRD · sold 3,000 at $25.00
75K
0.8% of stake
Jul 3010b5-1 plan
Susan Bobulsky
Chief Commercial Officer, MRD · sold 1,299 at $24.00
31K
0.3% of stake
Jul 2110b5-1 plan
Harlan S Robins
Chief Scientific Officer · sold 492,400 at avg $21.89
$10.8M
38% of stake
Jul 1610b5-1 plan
Susan Bobulsky
Chief Commercial Officer, MRD · sold 5,000 at $23.00
115K
1.2% of stake
Jul 1510b5-1 plan
Francis Lo
Chief People Officer · sold 105,762 at $22.59
$2.39M
31% of stake
Jul 210b5-1 plan
Harlan S Robins
Chief Scientific Officer · sold 386,240 at avg $22.01
$8.5M
27% of stake
Jul 1 – 210b5-1 plan
Francis Lo
Chief People Officer · sold 95,842 at avg $22.51
$2.16M
29% of stake
Jul 110b5-1 plan
Susan Bobulsky
Chief Commercial Officer, MRD · sold 487 at $22.00
11K
0.1% of stake
Jun 26 – 2910b5-1 plan
Sharon Benzeno
Chief Commercial Ofc Imm Med · sold 165,802 at avg $21.13
$3.5M
43% of stake
Jun 2510b5-1 plan
Susan Bobulsky
Chief Commercial Officer, MRD · sold 5,000 at $20.50
103K
1.2% of stake
Jun 2510b5-1 plan
Michelle Renee Griffin
Director · sold 52,084 at $20.18
$1.05M
77% of stake
Jun 15 – 1610b5-1 plan
Harlan S Robins
Chief Scientific Officer · sold 106,160 at avg $17.41
$1.85M
7.0% of stake
Jun 1110b5-1 plan
Susan Bobulsky
Chief Commercial Officer, MRD · sold 5,000 at $19.00
95K
1.2% of stake
Jun 410b5-1 plan
Susan Bobulsky
Chief Commercial Officer, MRD · sold 11,000 at $18.00
198K
2.6% of stake
Jun 410b5-1 plan
Francis Lo
Chief People Officer · sold 39,741 at $17.49
695K
14% of stake
May 18No plan
Kyle Piskel
Chief Financial Officer · sold 3,115 at $13.04
41K
1.2% of stake
Apr 2710b5-1 plan
Julie Rubinstein
President and COO · sold 19,037 at $14.23
271K
4.8% of stake
Apr 22 – 2410b5-1 plan
Julie Rubinstein
President and COO · sold 57,180 at avg $13.96
798K
13% of stake
Apr 17 – 2110b5-1 plan
Julie Rubinstein
President and COO · sold 69,061 at avg $14.60
$1.01M
15% of stake
Apr 14 – 1610b5-1 plan
Julie Rubinstein
President and COO · sold 57,180 at avg $14.45
826K
12% of stake
Apr 9 – 1310b5-1 plan
Julie Rubinstein
President and COO · sold 57,180 at avg $13.26
758K
12% of stake
Apr 810b5-1 plan
Harlan S Robins
Chief Scientific Officer · sold 10,000 at $14.85
149K
0.7% of stake
Apr 810b5-1 plan
Francis Lo
Chief People Officer · sold 22,564 at $15.07
340K
7.6% of stake
Apr 6 – 810b5-1 plan
Julie Rubinstein
President and COO · sold 69,061 at avg $14.34
991K
14% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ADPT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with ADPT

CompareIntrinsic value

VCELVericel Corporation

$45.48+10.68%65

IOVAIovance Biotherapeutics, Inc.

$8.70-1.47%10

VXRTVaxart Inc.

$0.40+0.00%84

IMCRImmunocore Holdings plc

$29.23-2.66%40

TWSTTwist Bioscience Corporation

$142.58+1.63%40

KRYSKrystal Biotech Inc.

$310.84+1.90%44

IBRXImmunityBio, Inc.

$8.45+1.87%30

BEAMBeam Therapeutics Inc.

$27.79+5.55%40

Held by ETFs

ADPT is in 56 US ETFs. The largest of them, with ADPT's weight in each:

Spot a number that looks wrong? Check it in ADPT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ADPT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.